Mine PubMed For Billion-Dollar Drug Ideas
Published on
Sam Parr
@thesamparr·May 8
Martin Shkreli came on MFM a while back and told Shaan and I something interesting:
PubMed has 40M+ biomedical papers.
It's the government database of every medical innovation ever logged.
And it's 100% free.
He told us if you sit there and read long enough you can become a billionaire.
In his case:
- Bristol-Myers had spent tens of millions developing a hypertension drug and quit on it.
- Shkreli's company eventually picked up the asset.
- Then he spent hours on PubMed and figured out the same compound could treat a rare kidney disease nobody was working on.
That drug is now FDA approved and the company (Travere Therapeutics) is worth ~$4B.
His takeaway was there are billion dollar opportunities hiding in plain sight, but they're hiding in "boring" stuff nobody wants to do.
That blue PubMed screen in the image looks boring on purpose. It’s a government website, not a pitch deck. But behind that plain search bar sits 40M+ biomedical papers, tens of billions of R&D spend, and a ridiculous number of abandoned ideas. If you treat that screen like a gold mine instead of homework, you can uncover neglected drugs, off-label uses, and weird little diseases with no competition.
Why this works better than brainstorming in a WeWork
The PubMed interface in the photo is ugly, but that’s the edge: zero branding, all signal. Big pharma regularly abandons promising compounds for political, portfolio, or timing reasons—not just science. If you’re willing to sit in front of that dull blue screen, grind through PDFs, and connect dots across disciplines, you’re effectively renting a multi-billion-dollar R&D lab for free. Most founders chase shiny AI tools; the leverage here is reading what 10,000 PhDs already discovered and deciding where the market simply… got bored.
How to turn that bland PubMed screen into a money printer
- Search for compounds or diseases where trials were stopped, then read why they were abandoned
- Look for papers showing strong results in tiny patient groups or rare conditions
- Cross-reference: “failed” hypertension drug + kidney disease + mechanism of action
- Hunt for treatments where biology looks solid but nobody’s running a current Phase 2/3 trial
- Package your insight into a tight memo investors or pharma partners can actually understand
Real-world proof that this PubMed grind pays
Travere Therapeutics turned an abandoned hypertension compound into an FDA‑approved treatment for a rare kidney disease by digging through PubMed data and reimagining the drug’s use.
Analyzed by Swipebot
Loading analysis...
